NGEN
NervGen Pharma Corp.
NASDAQ: NGEN · HEALTHCARE · BIOTECHNOLOGY
$3.63
-3.20% today
Updated 2026-04-30
Market cap
$311.58M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.45
Dividend yield
—
52W range
$2 – $6
Volume
0.2M
NervGen Pharma Corp. (NGEN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | $-13.12M | $-8.52M | $-11.70M | $-19.50M |
| Capital expenditures | $15570.00 | $4244.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — |
| Stock-based comp | $2.77M | $6.04M | $6.04M | $5.39M |
| Free cash flow | $-13.13M | $-8.53M | $-11.70M | $-19.50M |
| Investing cash flow | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Share repurchases | — | — | — | — |
| Debt repayment | — | — | — | — |
| Net change in cash | — | — | — | — |